Erschienen in:
01.12.2002 | Paper Report
Sequential tumour biopsies in phase I trials
verfasst von:
Fatima Cardoso
Erschienen in:
Breast Cancer Research
|
Ausgabe 1/2001
Einloggen, um Zugang zu erhalten
Excerpt
The development of new target-based anticancer drugs has led to the concept of "target modulation" and "optimal biological dose". It is critical to establish that the observed preclinical activity of a drug is in fact determined by the modulation of the intended target, and this should be achieved in early phase clinical trials. Another evolving notion relies on the observation that the maximum tolerated dose may not necessarily correspond to the optimal biological dose. However, a major obstacle to these new agents is the difficulty of obtaining relevant tumour tissue for laboratory analysis. …